Rituximab in the treatment of Graves' orbitopathy: latest updates and perspectives.
Graves’ disease
Graves’ orbitopathy
rituximab
thyroid eye disease
Journal
Endocrine connections
ISSN: 2049-3614
Titre abrégé: Endocr Connect
Pays: England
ID NLM: 101598413
Informations de publication
Date de publication:
01 Dec 2022
01 Dec 2022
Historique:
received:
19
09
2022
accepted:
11
10
2022
pubmed:
12
10
2022
medline:
12
10
2022
entrez:
11
10
2022
Statut:
epublish
Résumé
Graves' orbitopathy (GO) is a potentially sight-threatening and disfiguring, extrathyroidal manifestation of Graves' disease. It often impairs patients' quality of life, causing severe social and psychological sequelae. Intravenous glucocorticosteroids is currently the mainstay of therapy, but the efficacy is often underwhelming and recurrence rate is high. For many years, clinicians have been searching for new methods of treatment. Rituximab (RTX) is a chimeric monoclonal antibody targeted against CD20 which is a surface antigen present on B cells. It is frequently used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, or various types of vasculitis. Numerous clinical trials employing RTX in the treatment of GO have shown promising results. RTX is currently considered to be a valid second-line treatment option in patients unresponsive to previous interventions or in disease reactivation. This review summarizes the available literature on this topic, including two largest, randomized, controlled studies. Potential benefits, as well as the limitations of RTX therapy, are discussed.
Identifiants
pubmed: 36219838
doi: 10.1530/EC-22-0303
pii: e220303
pmc: PMC9716394
doi:
pii:
Types de publication
Journal Article
Review
Langues
eng
Références
Front Endocrinol (Lausanne). 2021 Jun 04;12:653627
pubmed: 34149612
Clin Endocrinol (Oxf). 2005 Feb;62(2):145-55
pubmed: 15670189
Clin Endocrinol (Oxf). 2013 Sep;79(3):437-42
pubmed: 23320840
Endokrynol Pol. 2017;68(5):498-504
pubmed: 28660988
Clin Endocrinol (Oxf). 1993 Apr;38(4):367-72
pubmed: 8319368
Intern Med. 2014;53(5):353-60
pubmed: 24583420
Curr Eye Res. 2020 Nov;45(11):1325-1341
pubmed: 32567373
J Clin Endocrinol Metab. 2007 Apr;92(4):1485-90
pubmed: 17244787
Lancet Diabetes Endocrinol. 2018 Apr;6(4):287-298
pubmed: 29396246
Graefes Arch Clin Exp Ophthalmol. 2020 Sep;258(9):2013-2021
pubmed: 32405700
Eur J Endocrinol. 2017 Feb;176(2):R101-R109
pubmed: 27760790
Clin Sci. 1945;5(3-4):177-94
pubmed: 21011937
Eur Thyroid J. 2020 Dec;9(Suppl 1):3-16
pubmed: 33511081
Endokrynol Pol. 2011;62 Suppl 1:1-7
pubmed: 22125104
Hormones (Athens). 2021 Jun;20(2):279-286
pubmed: 33783712
J Neuroophthalmol. 2014 Jun;34(2):177-85
pubmed: 24821101
N Engl J Med. 2017 May 4;376(18):1748-1761
pubmed: 28467880
J Clin Endocrinol Metab. 2013 Apr;98(4):1443-9
pubmed: 23408569
Expert Rev Ophthalmol. 2017;12(2):111-121
pubmed: 28775762
Front Endocrinol (Lausanne). 2020 Nov 30;11:615993
pubmed: 33329408
J Clin Endocrinol Metab. 2015 Feb;100(2):422-31
pubmed: 25494967
J Clin Endocrinol Metab. 2013 Nov;98(11):4291-9
pubmed: 24009135
Ophthalmic Plast Reconstr Surg. 2004 May;20(3):224-5
pubmed: 15167731
Clin Endocrinol (Oxf). 2017 Feb;86(2):247-255
pubmed: 27484048
Eur J Ophthalmol. 2020 Sep;30(5):1008-1013
pubmed: 31025590
Clin Rheumatol. 2019 Nov;38(11):2977-2994
pubmed: 31367943
Surv Ophthalmol. 2010 May-Jun;55(3):215-26
pubmed: 20385333
Front Endocrinol (Lausanne). 2022 Jan 25;12:790246
pubmed: 35145479
Ocul Immunol Inflamm. 2022 Feb 17;30(2):500-505
pubmed: 32965148
J Clin Endocrinol Metab. 2007 May;92(5):1769-72
pubmed: 17284622
N Engl J Med. 2020 Jan 23;382(4):341-352
pubmed: 31971679
Clin Exp Immunol. 2010 Sep;161(3):436-43
pubmed: 20529087
Ann Rheum Dis. 2013 Sep 1;72(9):1496-502
pubmed: 23136242
Int J Rheum Dis. 2015 Feb;18(2):154-63
pubmed: 25522652
Clin Endocrinol (Oxf). 2019 Jul;91(1):179-186
pubmed: 30864162
J Clin Endocrinol Metab. 2015 Feb;100(2):432-41
pubmed: 25343233
Thyroid. 2021 May;31(5):821-828
pubmed: 33234032
Arch Ophthalmol. 2012 Jan;130(1):122-4
pubmed: 22232486
Best Pract Res Clin Endocrinol Metab. 2020 Jan;34(1):101388
pubmed: 32059832
Ophthalmology. 2010 Jan;117(1):133-139.e2
pubmed: 19818507
Clin Immunol. 2009 Mar;130(3):252-8
pubmed: 18964302
J Clin Endocrinol Metab. 1996 Aug;81(8):2976-9
pubmed: 8768861
Eur J Endocrinol. 2021 Aug 27;185(4):G43-G67
pubmed: 34297684
Horm Metab Res. 2011 Mar;43(3):194-9
pubmed: 21283953
J Clin Endocrinol Metab. 2022 Feb 17;107(3):743-754
pubmed: 34687316
Eur J Endocrinol. 2006 May;154(5):623-32
pubmed: 16645007
Eur J Endocrinol. 2008 Nov;159(5):609-15
pubmed: 18628345
N Engl J Med. 2010 Feb 25;362(8):726-38
pubmed: 20181974
Immunol Lett. 2003 Jul 3;88(1):85-6
pubmed: 12853167
Horm Metab Res. 2012 Dec;44(13):957-61
pubmed: 22752955
J Endocrinol Invest. 2006 Dec;29(11):1012-6
pubmed: 17259800
Yonsei Med J. 2013 Jul;54(4):1033-9
pubmed: 23709442
Clin Endocrinol (Oxf). 2013 Aug;79(2):145-51
pubmed: 23581474
Eur J Endocrinol. 2006 Apr;154(4):511-7
pubmed: 16556712
J Clin Endocrinol Metab. 1995 Sep;80(9):2830-3
pubmed: 7673432
Clin Immunol. 2005 Dec;117(3):207-13
pubmed: 16169773
Am J Transplant. 2006 May;6(5 Pt 1):859-66
pubmed: 16611321
Eur J Endocrinol. 2005 Feb;152(2):171-7
pubmed: 15745922
Am J Pathol. 2002 Jul;161(1):195-206
pubmed: 12107104
J Clin Endocrinol Metab. 2016 Jun;101(6):2340-7
pubmed: 27043163
Best Pract Res Clin Endocrinol Metab. 2012 Jun;26(3):291-302
pubmed: 22632366